Cargando…
Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase
Genetic modification of human T cells to express transgene-encoded polypeptides, such as tumor targeting chimeric antigen receptors, is an emerging therapeutic modality showing promise in clinical trials. The development of simple and efficient techniques for purifying transgene(+) T cells is needed...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028078/ https://www.ncbi.nlm.nih.gov/pubmed/23303282 http://dx.doi.org/10.1038/gt.2012.97 |
_version_ | 1782317031286112256 |
---|---|
author | Jonnalagadda, Mahesh Brown, Christine E. Chang, Wen C. Ostberg, Julie R. Forman, Stephen J. Jensen, Michael C. |
author_facet | Jonnalagadda, Mahesh Brown, Christine E. Chang, Wen C. Ostberg, Julie R. Forman, Stephen J. Jensen, Michael C. |
author_sort | Jonnalagadda, Mahesh |
collection | PubMed |
description | Genetic modification of human T cells to express transgene-encoded polypeptides, such as tumor targeting chimeric antigen receptors, is an emerging therapeutic modality showing promise in clinical trials. The development of simple and efficient techniques for purifying transgene(+) T cells is needed to facilitate the derivation of cell products with uniform potency and purity. Unlike selection platforms that utilize physical methods (immunomagnetic or sorting) that are technically cumbersome and limited by the expense and availability of clinical-grade components, we focused on designing a selection system based on the pharmaceutical drug methotrexate (MTX), a potent allosteric inhibitor of human dihydrofolate reductase (DHFR). Here, we describe the development of SIN lentiviral vectors that direct the coordinated expression of a CD19-specific CAR, the human EGFRt tracking/suicide construct, and a methotrexate-resistant human DHFR mutein (huDHFR(FS); L22F, F31S). Our results demonstrate that huDHFR(FS) co-expression renders lentivirally transduced primary human CD45RO(+)CD62L(+) central memory T cells resistant to lymphotoxic concentrations of MTX up to 0.1 µM. Our modular cDNA design insures that selected MTX-resistant T cells co-express functionally relevant levels of the CD19-specific CAR and EGFRt. This selection system based on huDHFR(FS) and MTX has considerable potential utility in the manufacturing of clinical-grade T cell products. |
format | Online Article Text |
id | pubmed-4028078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
record_format | MEDLINE/PubMed |
spelling | pubmed-40280782014-05-20 Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase Jonnalagadda, Mahesh Brown, Christine E. Chang, Wen C. Ostberg, Julie R. Forman, Stephen J. Jensen, Michael C. Gene Ther Article Genetic modification of human T cells to express transgene-encoded polypeptides, such as tumor targeting chimeric antigen receptors, is an emerging therapeutic modality showing promise in clinical trials. The development of simple and efficient techniques for purifying transgene(+) T cells is needed to facilitate the derivation of cell products with uniform potency and purity. Unlike selection platforms that utilize physical methods (immunomagnetic or sorting) that are technically cumbersome and limited by the expense and availability of clinical-grade components, we focused on designing a selection system based on the pharmaceutical drug methotrexate (MTX), a potent allosteric inhibitor of human dihydrofolate reductase (DHFR). Here, we describe the development of SIN lentiviral vectors that direct the coordinated expression of a CD19-specific CAR, the human EGFRt tracking/suicide construct, and a methotrexate-resistant human DHFR mutein (huDHFR(FS); L22F, F31S). Our results demonstrate that huDHFR(FS) co-expression renders lentivirally transduced primary human CD45RO(+)CD62L(+) central memory T cells resistant to lymphotoxic concentrations of MTX up to 0.1 µM. Our modular cDNA design insures that selected MTX-resistant T cells co-express functionally relevant levels of the CD19-specific CAR and EGFRt. This selection system based on huDHFR(FS) and MTX has considerable potential utility in the manufacturing of clinical-grade T cell products. 2013-01-10 2013-08 /pmc/articles/PMC4028078/ /pubmed/23303282 http://dx.doi.org/10.1038/gt.2012.97 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Jonnalagadda, Mahesh Brown, Christine E. Chang, Wen C. Ostberg, Julie R. Forman, Stephen J. Jensen, Michael C. Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase |
title | Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase |
title_full | Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase |
title_fullStr | Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase |
title_full_unstemmed | Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase |
title_short | Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase |
title_sort | efficient selection of genetically modified human t cells using methotrexate-resistant human dihydrofolate reductase |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028078/ https://www.ncbi.nlm.nih.gov/pubmed/23303282 http://dx.doi.org/10.1038/gt.2012.97 |
work_keys_str_mv | AT jonnalagaddamahesh efficientselectionofgeneticallymodifiedhumantcellsusingmethotrexateresistanthumandihydrofolatereductase AT brownchristinee efficientselectionofgeneticallymodifiedhumantcellsusingmethotrexateresistanthumandihydrofolatereductase AT changwenc efficientselectionofgeneticallymodifiedhumantcellsusingmethotrexateresistanthumandihydrofolatereductase AT ostbergjulier efficientselectionofgeneticallymodifiedhumantcellsusingmethotrexateresistanthumandihydrofolatereductase AT formanstephenj efficientselectionofgeneticallymodifiedhumantcellsusingmethotrexateresistanthumandihydrofolatereductase AT jensenmichaelc efficientselectionofgeneticallymodifiedhumantcellsusingmethotrexateresistanthumandihydrofolatereductase |